Abstract | PURPOSE: PATIENTS AND METHODS: Sixty patients with unresectable stage III NSCLC were treated with two cycles of paclitaxel 175 mg/m2 and carboplatin (area under the time-concentration curve = 6), followed by thoracic radiotherapy (64 Gy) with concurrent weekly paclitaxel 60 mg/m2. Patients were randomly assigned to receive 740 mg/m2 of amifostine (arm A) or placebo (arm B) before each dose of paclitaxel and carboplatin. Treatment-related toxicities were evaluated at each visit and nerve conduction tests were performed before and after treatment for the objective assessment of neurotoxicity. RESULTS: There was no significant difference between arms A and B in grade 3 to 4 neutropenia. In all 72 neurophysiological parameters measured, there was no significant difference between the two treatment arms, although there was a trend toward fewer patients showing deterioration in arm A for six of the parameters. Grade 2 to 3 esophagitis occurred in 43% of patients in arm A and in 70% of patients in arm B. The difference of -27% (95% confidence limit = -50%, 0.4%) was not statistically significant. Response rates and survival were also not significantly different between the two arms. CONCLUSION:
|
Authors | Swan Swan Leong, Eng Huat Tan, Kam Weng Fong, Einar Wilder-Smith, Yew Kwang Ong, Bee Choo Tai, Lita Chew, Shih Hui Lim, Joseph Wee, Khai Mun Lee, Kian Fong Foo, Peter Ang, Peng Tiam Ang |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 21
Issue 9
Pg. 1767-74
(May 01 2003)
ISSN: 0732-183X [Print] United States |
PMID | 12721253
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Placebos
- Radiation-Protective Agents
- Carboplatin
- Amifostine
- Paclitaxel
|
Topics |
- Adult
- Aged
- Amifostine
(administration & dosage, pharmacology)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Carboplatin
(administration & dosage)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, pathology, radiotherapy)
- Combined Modality Therapy
- Double-Blind Method
- Esophagitis
(etiology, prevention & control)
- Female
- Humans
- Infusions, Intravenous
- Lung Neoplasms
(drug therapy, pathology, radiotherapy)
- Male
- Middle Aged
- Paclitaxel
(administration & dosage)
- Placebos
- Radiation Injuries
(prevention & control)
- Radiation-Protective Agents
(administration & dosage, pharmacology)
- Treatment Outcome
|